Five-year follow-up of patients treated for 1 year with octreotide long-acting release for enterochromaffin-like cell carcinoids

References

• Gough DB, Thompson GB, Crotty TB, Donohue JH, Kvols LK, Carney JA, Diverse clinical and pathologic features of gastric carcinoid and the relevance of hypergastrinemia. World J Surg 1994;18:473–9; discussion 479–80.
   Google Scholar
• Rindi G, Luinetti O, Cornaggia M, Capella C, Solcia E. Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma: a clinicopathologic study. Gastroenterology 1993;104:994–1006.
   PubMed Web of Science ®Google Scholar
• Trudeau WL, McGuigan JE. Relations between serum gastrin levels and rates of gastric hydrochloric acid secretion. N Engl J Med 1971;284:408–12.
   PubMed Web of Science ®Google Scholar
• McGuigan JE, Trudeau WL. Serum gastrin concentrations in pernicious anemia. N Engl J Med 1970;282:358–61.
   PubMed Web of Science ®Google Scholar
• Ryberg B, Tielemans Y, Axelson J, Carlsson E, Hakanson R, Mattson H, Gastrin stimulates the self-replication rate of enterochromaffinlike cells in the rat stomach. Effects of omeprazole, ranitidine, and gastrin-17 in intact and antrectomized rats. Gastroenterology 1990;99:935–42.
   PubMed Web of Science ®Google Scholar
• Hakanson R, Tielemans Y, Chen D, Andersson K, Mattsson H, Sundler F. Time-dependent changes in enterochromaffin-like cell kinetics in stomach of hypergastrinemic rats. Gastroenterology 1993;105:15–21.
   PubMed Web of Science ®Google Scholar
• Brenna E, Waldum HL. Trophic effect of gastrin on the enterochromaffin like cells of the rat stomach: establishment of a dose response relationship. Gut 1992;33:1303–6.
   PubMed Web of Science ®Google Scholar
• Borch K, Renvall H, Liedberg G. Gastric endocrine cell hyperplasia and carcinoid tumors in pernicious anemia. Gastroenterology 1985;88:638–48.
   PubMed Web of Science ®Google Scholar
• Kokkola A, Sjoblom SM, Haapiainen R, Sipponen P, Puolakkainen P, Jarvinen H. The risk of gastric carcinoma and carcinoid tumours in patients with pernicious anaemia. A prospective follow-up study. Scand J Gastroenterol 1998;33:88–92.
   PubMed Web of Science ®Google Scholar
• Zamcheck N, Grable E, Ley A, Norman L. Occurrence of gastric cancer among patients with pernicious anemia at the Boston city hospital. N Engl J Med 1955;252:1103–10.
   PubMed Web of Science ®Google Scholar
• Taupenot L, Harper KL, O'Connor DT. The chromogranin-secretogranin family. N Engl J Med 2003;348:1134–49.
   PubMed Web of Science ®Google Scholar
• Syversen U, Jacobsen MB, O'Connor DT, Ronning K, Waldum HL. Immunoassays for measurement of chromogranin a and pancreastatin-like immunoreactivity in humans: correspondence in patients with neuroendocrine neoplasia. Neuropeptides 1994;26:201–6.
   PubMed Web of Science ®Google Scholar
• Nobels FR, Kwekkeboom DJ, Coopmans W, Schoenmakers CH, Lindemans J, De Herder WW, Chromogranin a as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones. J Clin Endocrinol Metab 1997;82:2622–8.
   PubMed Web of Science ®Google Scholar
• Borch K, Stridsberg M, Burman P, Rehfeld JF. Basal chromogranin a and gastrin concentrations in circulation correlate to endocrine cell proliferation in type-a gastritis. Scand J Gastroenterol 1997;32:198–202.
   PubMed Web of Science ®Google Scholar
• Hakanson R, Ding XQ, Norlen P, Chen D. Circulating pancreastatin is a marker for the enterochromaffin-like cells of the rat stomach. Gastroenterology 1995;108:1445–52.
   PubMedGoogle Scholar
• Waldum HL, Syversen U. Chromogranin a (cga) and the enterochromaffin-like (ecl) cell. Adv Exp Med Biol 2000;482:361–7.
   PubMed Web of Science ®Google Scholar
• Soga J. Gastric carcinoids: a statistical evaluation of 1,094 cases collected from the literature. Surg Today 1997;27:892–901.
   PubMedGoogle Scholar
• Rappel S, Altendorf-Hofmann A, Stolte M. Prognosis of gastric carcinoid tumours. Digestion 1995;56:455–62.
   PubMed Web of Science ®Google Scholar
• Rindi G, Azzoni C, La Rosa S, Klersy C, Paolotti D, Rappel S, Ecl cell tumor and poorly differentiated endocrine carcinoma of the stomach: prognostic evaluation by pathological analysis. Gastroenterology 1999;116:532–42.
   PubMed Web of Science ®Google Scholar
• Borch K, Ahren B, Ahlman H, Falkmer S, Granerus G, Grimelius L. Gastric carcinoids: biologic behavior and prognosis after differentiated treatment in relation to type. Ann Surg 2005;242:64–73.
   PubMed Web of Science ®Google Scholar
• Modlin IM, Lye KD, Kidd M. Carcinoid tumors of the stomach. Surg Oncol 2003;12:153–72.
   PubMed Web of Science ®Google Scholar
• Higham AD, Dimaline R, Varro A, Attwood S, Armstrong G, Dockray GJ, Thompson DG. Octreotide suppression test predicts beneficial outcome from antrectomy in a patient with gastric carcinoid tumor. Gastroenterology 1998;114:817–22.
   PubMed Web of Science ®Google Scholar
• Oberg K, Norheim I, Theodorsson E, Ahlman H, Lundqvist G, Wide L. The effects of octreotide on basal and stimulated hormone levels in patients with carcinoid syndrome. J Clin Endocrinol Metab 1989;68:796–800.
   PubMed Web of Science ®Google Scholar
• Rinke A, Muller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide lar in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the promid study group. J Clin Oncol 2009;27(28):4656–63.
   PubMed Web of Science ®Google Scholar
• Fykse V, Sandvik AK, Qvigstad G, Falkmer SE, Syversen U, Waldum HL. Treatment of ecl cell carcinoids with octreotide lar. Scand J Gastroenterol 2004;39:621–8.
   PubMed Web of Science ®Google Scholar
• Grozinsky-Glasberg S, Kaltsas G, Gur C, Gal E, Thomas D, Fichman S, Long-acting somatostatin analogues are an effective treatment for type 1 gastric carcinoid tumours. Eur J Endocrinol 2008;159:475–82.
   PubMed Web of Science ®Google Scholar
• Jianu CS, Fossmark R, Syversen U, Hauso O, Waldum HL. A meal test improves the specificity of chromogranin a as a marker of neuroendocrine neoplasia. Tumour Biol 2010;31(5):373–80.
   PubMedGoogle Scholar
• Campana D, Nori F, Pezzilli R, Piscitelli L, Santini D, Brocchi E, Gastric endocrine tumors type i: treatment with long-acting somatostatin analogs. Endocr Relat Cancer 2008;15:337–42.
   PubMed Web of Science ®Google Scholar
• Fykse V, Sandvik AK, Waldum HL. One-year follow-up study of patients with enterochromaffin-like cell carcinoids after treatment with octreotide long-acting release. Scand J Gastroenterol 2005;40:1269–74.
   PubMed Web of Science ®Google Scholar
• Khuroo MS, Khuroo MS, Khuroo NS. Treatment of type i gastric neuroendocrine tumors with somatostatin analogs. J Gastroenterol Hepatol 2009;25:548–54.
   Google Scholar
• Qvigstad G, Qvigstad T, Westre B, Sandvik AK, Brenna E, Waldum HL. Neuroendocrine differentiation in gastric adenocarcinomas associated with severe hypergastrinemia and/or pernicious anemia. Apmis 2002;110:132–9.
   PubMed Web of Science ®Google Scholar
• Kleveland PM, Haugen SE, Waldum HL. The preparation of bioactive 125i-gastrin, using iodo-gen as oxidizing agent, and the use of this tracer in receptor studies. Scand J Gastroenterol 1985;20:569–76.
   PubMed Web of Science ®Google Scholar
• Modlin IM, Lye KD, Kidd M. A 50-year analysis of 562 gastric carcinoids: small tumor or larger problem? Am J Gastroenterol 2004;99:23–32.
   PubMed Web of Science ®Google Scholar
• Bordi C. Gastric carcinoids. Ital J Gastroenterol Hepatol 1999;31(Suppl 2):S94–7.
   Google Scholar
• Rindi G, Bordi C, Rappel S, La Rosa S, Stolte M, Solcia E. Gastric carcinoids and neuroendocrine carcinomas: pathogenesis, pathology, and behavior. World J Surg 1996;20:168–72.
   PubMed Web of Science ®Google Scholar
• Sjoblom SM, Sipponen P, Jarvinen H. Gastroscopic follow up of pernicious anaemia patients. Gut 1993;34:28–32.
   PubMed Web of Science ®Google Scholar
• Qvigstad G, Falkmer S, Westre B, Waldum HL. Clinical and histopathological tumour progression in ecl cell carcinoids (“Eclomas”). Apmis 1999;107:1085–92.
   PubMed Web of Science ®Google Scholar
• Waldum HL, Qvigstad G, Fossmark R, Kleveland PM, Sandvik AK. Rebound acid hypersecretion from a physiological, pathophysiological and clinical viewpoint. Scand J Gastroenterol 2010;45:389–94.
   PubMed Web of Science ®Google Scholar
• Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 1965;64:31–49.
   PubMedGoogle Scholar
• Borch K. Atrophic gastritis and gastric carcinoid tumours. Ann Med 1989;21:291–7.
   PubMed Web of Science ®Google Scholar
• Sjoblom SM, Sipponen P, Miettinen M, Karonen SL, Jrvinen HJ. Gastroscopic screening for gastric carcinoids and carcinoma in pernicious anemia. Endoscopy 1988;20:52–6.
   PubMed Web of Science ®Google Scholar
• Waldum HL, Haugen OA, Isaksen C, Mecsei R, Sandvik AK. Enterochromaffin-like tumour cells in the diffuse but not the intestinal type of gastric carcinomas. Scand J Gastroenterol Suppl 1991;180:165–9.
   PubMedGoogle Scholar
• Waldum HL, Burhol PG. The effect of somatostatin on serum group i pepsinogens (pg i), serum gastrin, and gastric h+ and pepsin secretion in man. Scand J Gastroenterol 1980;15:425–31.
   PubMed Web of Science ®Google Scholar